ERBB2 and breast carcinoma: As a result, the median overall survival (OS) of metastatic HER2-positive breast cancer patients has reached 56 months.1 Despite effective new agents, metastatic breast cancer remains incurable since the tumours eventually acquire resistance to the agents.